Seven companies have been highlighted in Clarivate’s ‘Companies to Watch Report’ for delivering more effective and safer medicines to market faster by leveraging artificial intelligence (AI) and machine learning (ML) technology. From identifying novel targets to simulating how drugs will function in the human body, Clarivate… Read More
AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method… Read More
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More
In this webinar, hosted by DDW and co-sponsored by Benchling and Proscia, you will learn about the key benefits and latest innovations to be aware of in AI and lab automation. You will hear from Jeremy Skillington, CEO of Poolbeg Pharma, as well as sponsor presentations from Helen Liu-Mayo, Product… Read More
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes, as well as continued company growth through… Read More
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More
Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com. However, the change AI will bring about in drug discovery will take some time, according to the ‘Global Markets… Read More
AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers. The collaboration will combine Intelligent OMICS’ AI platform, which uses multi-omics data and deep learning algorithms to uncover therapeutic opportunities for treatment,… Read More
Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. In this new App Note, discover the benefits of Evident’s CM cell culture monitors, which provide label-free, quantitative results, consistent results throughout your lab, and are… Read More
Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. Evident’s CM cell culture monitors provide label-free, quantitative results, consistent results throughout your lab, and are cost-effective. Researchers at ACEL simplified the cell migration process by… Read More
AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team, respectively focusing on R&D and Application Science in the newly-created BioPharmics Division. BioPharmics has developed a series of algorithms and… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More
News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More
A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development. Genesis will also invest in continued development of generative and predictive AI methods, which form the foundation of the Genesis… Read More
A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology… Read More
